The meeting is in SAN FRANCISCO BAY AREA on November 3-5, 2013. To view the program, submit an abstract, or register for the meeting, go to the website:.. A new strategy to drive back HIV infection An effective vaccine against HIV-1 remains elusive, but 1 promising strategy targets designer antibodies that have very much broader potency than most regular, specific antibodies exquisitely. These broadly neutralizing antibodies can handle the high mutation price of HIV particles which makes normal, very particular antibodies ineffective within a short space of time. A report published by Cell Press on March 28th in the journal Cell reveals astonishing mutations in these antibodies that are crucial for strong protection against HIV-1.The participants were women infected with HIV-1 who have been not pregnant or breast-feeding, at 10 African sites . Their screening CD4+ T-cell counts were less than 200 per cubic millimeter, and they had not received antiretroviral therapy previously, with two exceptions: trial 1 individuals had received single-dosage nevirapine on one or more occasions 6 or even more a few months before enrollment, and individuals in both trials were permitted to have received up to 10 weeks of treatment with zidovudine, with the last dosage taken at least six months before study entry. Participants were followed for at least 48 weeks after the last patient was enrolled.